Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 05, 2021

SELL
$29.97 - $37.17 $7,672 - $9,515
-256 Closed
0 $0
Q1 2021

May 07, 2021

SELL
$29.24 - $42.03 $526 - $756
-18 Reduced 6.57%
256 $8,000
Q4 2020

Jan 13, 2021

SELL
$35.35 - $50.67 $3,464 - $4,965
-98 Reduced 26.34%
274 $10,000
Q3 2020

Nov 12, 2020

SELL
$35.98 - $47.66 $14,176 - $18,778
-394 Reduced 51.44%
372 $14,000
Q2 2020

Aug 13, 2020

SELL
$45.06 - $67.74 $49,926 - $75,055
-1,108 Reduced 59.12%
766 $35,000
Q1 2020

May 12, 2020

BUY
$40.01 - $73.97 $61,375 - $113,469
1,534 Added 451.18%
1,874 $89,000
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $13,382 - $26,112
340 New
340 $13,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Sowell Financial Services LLC Portfolio

Follow Sowell Financial Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sowell Financial Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sowell Financial Services LLC with notifications on news.